EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 40 / No 11 (Novembre 2024) Med Sci (Paris), 40 11 (2024) 837-847 References
Free Access
Issue
Med Sci (Paris)
Volume 40, Number 11, Novembre 2024
Page(s) 837 - 847
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2024153
Published online 10 December 2024
  1. https://www.has-sante.fr/jcms/p_3191108/fr/strategie-therapeutique-du-patient-vivant-avec-un-diabete-de-type-2 [Google Scholar]
  2. Fosse-Edorh S, Fagot-Campagna A, Detournay B, et al. Impact of socio-economic position on health and quality of care in adults with type 2 diabetes in France : the Entred 2007 study. Diabet Med 2015 ; 32 : 1438–44. [CrossRef] [PubMed] [Google Scholar]
  3. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26 : Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998 ; 15 : 297–303. [CrossRef] [PubMed] [Google Scholar]
  4. Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes 2019 ; 12 : 1973–85. [CrossRef] [Google Scholar]
  5. Starling EH. The chemical correlation of the functions of the body. Lancet 1905 ; 2 : 339–41. [Google Scholar]
  6. La Barre MJ. Sur les possibilités d’un traitement du diabète par l’incrétine. Bull Mem Acad R Med Belg 1932 ; 12 : 620–34. [Google Scholar]
  7. Berson SA, Yalow RS, Bauman A, et al. Insulin-I 131 metabolism in human subjects : demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest 1956 ; 35 : 170–90. [CrossRef] [PubMed] [Google Scholar]
  8. John H. Glucose tolerance and its value in diagnosis. J Metab Res 1992 ; 1 : 497–548. [Google Scholar]
  9. McIntryre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964 ; 4 : 20–1. [CrossRef] [Google Scholar]
  10. Elrick H, Stimmler L, Hlad CJ Jr, Aray Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964 ; 24 : 1076–82. [CrossRef] [PubMed] [Google Scholar]
  11. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969 ; 123 : 261–6. [CrossRef] [PubMed] [Google Scholar]
  12. Creutzfeldt W, Ebert R, Nauck M, Strckmann F. Disturbances of the entero-insular axis. Scand J Gastroenterol 1983 ; 18 : 111–9. [Google Scholar]
  13. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 ; 29 : 46–52. [CrossRef] [PubMed] [Google Scholar]
  14. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018 ; 27 : 740–56. [CrossRef] [PubMed] [Google Scholar]
  15. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes : physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016 ; 4 : 525–36. [CrossRef] [PubMed] [Google Scholar]
  16. Margolskee RF, Dyer J, Kokrashvili Z, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007 ; 104 : 15075–80. [CrossRef] [PubMed] [Google Scholar]
  17. Dotson CD, Zhang L, Xu H, et al. Bitter taste receptors influence glucose homeostasis. PLoS One 2008 ; 3 : e3974. [CrossRef] [PubMed] [Google Scholar]
  18. McLean BA, Wong CK, Campbell JE, et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 2021 ; 42 : 101–32. [CrossRef] [PubMed] [Google Scholar]
  19. Usdin TB, Mezey E, Button DC, et al. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993 ; 133 : 2861–70. [CrossRef] [PubMed] [Google Scholar]
  20. Holst J. J. The physiology of glucagon-like peptide 1. Physiol Rev 2007 ; 87 : 1409–39. [CrossRef] [PubMed] [Google Scholar]
  21. D’Alessio D, Lu W, Sun W, et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma : evidence for selective release of GLP-1 in the lymph system. Am J Physiol 2007 ; 293 : R2163–9. [Google Scholar]
  22. Bohórquez DV, Liddle RA. The gut connectome : making sense of what you eat. J Clin Invest 2015 ; 125 : 888–90. [CrossRef] [PubMed] [Google Scholar]
  23. Mussa BM, Verberne AJ. The dorsal motor nucleus of the vagus and regulation of pancreatic secretory function. Exp Physiol 2013 ; 98 : 25–37. [CrossRef] [PubMed] [Google Scholar]
  24. Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007 ; 148 : 4965–73. [CrossRef] [PubMed] [Google Scholar]
  25. Burcelin R, Da Costa A, Drucker D, et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001 ; 50 : 1720–8. [CrossRef] [PubMed] [Google Scholar]
  26. Buller S, Blouet C. Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss. Am J Physiol Endocrinol Metab 2024 ; 326 : E472–80. [CrossRef] [PubMed] [Google Scholar]
  27. Wan S, Coleman FH, Travagli RA. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest Liver Physiol 2007 ; 292, G1474–82. [CrossRef] [PubMed] [Google Scholar]
  28. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019 ; 30 : 72–130. [Google Scholar]
  29. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal a-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970 ; 283 : 109–15. [CrossRef] [PubMed] [Google Scholar]
  30. Gandasi NR, Gao R, Kothegala L, et al. GLP-1 metabolite GLP-1(9-36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia 2024 ; 67 : 528–46. [CrossRef] [PubMed] [Google Scholar]
  31. Cheruiyot A, Hollister-Lock J, Sullivan B, et al. Sustained hyperglycemia specifically targets translation of mRNAs for insulin secretion. J Clin Invest 2023 ; 134 : e173280. [CrossRef] [PubMed] [Google Scholar]
  32. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993 ; 91 : 301–7. [CrossRef] [PubMed] [Google Scholar]
  33. Hu EH, Tsai ML, Lin Y, et al. A Review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists. Medicina (Kaunas) 2024 ; 60 : 357. [CrossRef] [PubMed] [Google Scholar]
  34. Tricco AC, Antony J, Khan PA, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents : a systematic review and network meta-analysis. BMJ Open 2014 ; 4 : e005752. [CrossRef] [PubMed] [Google Scholar]
  35. Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagon like peptide-I-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 1992 ; 15 : 270–6. [CrossRef] [PubMed] [Google Scholar]
  36. Eng J. Exendin peptides. Mt. Sinai J Med 1992 ; 59 : 147–9. [Google Scholar]
  37. Knop FK, Brønden A, Vilsbøll T. Exenatide : pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 2017 ; 18 : 555–71. [CrossRef] [PubMed] [Google Scholar]
  38. Moon S, Lee J, Chung HS, et al. Efficacy and safety of the new appetite suppressant, Liraglutide : A meta-analysis of randomized controlled trials. Endocrinol Metab (Seoul) 2021 ; 36 : 647–60. [CrossRef] [PubMed] [Google Scholar]
  39. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010 ; 26, : 287–96. [CrossRef] [PubMed] [Google Scholar]
  40. Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes : a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev 2016 ; 32 : 776–90. [CrossRef] [PubMed] [Google Scholar]
  41. Bonora E, Frias JP, Tinahones FJ, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes : Exploratory analyses of AWARD-11. Diabetes Obes Metab 2021 ; 23 : 2242–50. [CrossRef] [PubMed] [Google Scholar]
  42. Frias JP, Bonora E, Cox DA, et al. Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup : Post hoc analysis of AWARD-11. Diabetes Obes Metab 2021 ; 23 : 2819–24. [CrossRef] [PubMed] [Google Scholar]
  43. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019 ; 10 : 155. [CrossRef] [PubMed] [Google Scholar]
  44. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022 ; 23 : 521–39. [CrossRef] [PubMed] [Google Scholar]
  45. Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs 2021 ; 81 : 1003–30. [CrossRef] [PubMed] [Google Scholar]
  46. Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes : A systematic review and meta-analysis. Diabetes Obes Metab 2020 ; 22 : 335–45. [CrossRef] [PubMed] [Google Scholar]
  47. Larger E. Un analogue du glucagon-like peptide 1 (GLP1) administré par voie orale : une nouveauté dans le traitement du diabète de type 2. Med Sci (Paris) 2021 ; 37 : 53–8. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  48. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996 ; 2 : 1254–8. [CrossRef] [PubMed] [Google Scholar]
  49. Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab 2019 ; 20 : 51–62. [Google Scholar]
  50. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013 ; 5 : 209ra151. [CrossRef] [PubMed] [Google Scholar]
  51. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021 ; 385 : 503–15. [CrossRef] [PubMed] [Google Scholar]
  52. Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, et al. 100 years of glucagon and 100 more. Diabetologia 2023 ; 66 : 1378–94. [CrossRef] [PubMed] [Google Scholar]
  53. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes : a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022 ; 400 : 1869–81. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.